Observational studyCancer medicine2026
Predictors of Hospitalization due to Febrile Neutropenia in Cancer Patients Receiving Chemotherapy.
Observational study in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFebrile neutropenia (FN) is a serious and potentially life-threatening complication of chemotherapy, frequently leading to hospitalization, treatment delays, and increased healthcare utilization. Identifying clinical factors associated with FN-related hospital admission is essential for improving risk stratification and supportive care strategies.
methodsThis observational study evaluated cancer patients 2207 receiving chemotherapy who developed FN. Clinical, laboratory, and treatment-related variables-including body mass index (BMI), hemoglobin level, absolute neutrophil count, chemotherapy cycle number, Eastern Cooperative Oncology Group (ECOG) performance status, and granulocyte colony-stimulating factor (G-CSF) prophylaxis-were analyzed. Multivariable logistic regression was performed to determine independent predictors of FN-related hospitalization.
resultsFN-related hospitalization was associated not only with neutrophil count but also with multiple clinical parameters. Lower hemoglobin levels, poorer ECOG performance status, lower chemotherapy cycle number, and BMI were identified as independent predictors. The inverse association between chemotherapy cycle number and hospitalization risk (OR = 0.96) supports the established pattern of FN occurring more frequently during early treatment cycles. Patients requiring hospitalization had a lower mean number of chemotherapy cycles, consistent with early-cycle vulnerability. Although the model demonstrated statistical significance, its explanatory power was modest (Nagelkerke R
conclusionFN-related hospitalization in patients receiving chemotherapy is influenced by multidimensional clinical factors beyond neutrophil count alone. Performance status, hematologic reserve, BMI, and treatment timing play important roles in risk determination. Early identification of high-risk patients and implementation of individualized monitoring and prophylactic strategies may improve patient safety and optimize healthcare resource utilization. Prospective, multicenter studies are warranted to develop and validate risk-based care models aimed at reducing FN-related hospitalizations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.